FibroGen, Inc (NASDAQ:FGEN) Director Jorma Routti sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $47.25, for a total value of $567,000.00. Following the sale, the director now owns 133,840 shares of the company’s stock, valued at $6,323,940. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

FibroGen, Inc (NASDAQ:FGEN) opened at $44.85 on Thursday. FibroGen, Inc has a twelve month low of $19.25 and a twelve month high of $60.15. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FGEN. FMR LLC lifted its holdings in FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after acquiring an additional 1,641,423 shares during the last quarter. EcoR1 Capital LLC lifted its holdings in FibroGen by 3,674.1% in the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock valued at $51,210,000 after acquiring an additional 1,543,448 shares during the last quarter. Janus Henderson Group PLC acquired a new position in FibroGen in the second quarter valued at approximately $45,633,000. Eagle Asset Management Inc. acquired a new position in FibroGen in the third quarter valued at approximately $46,158,000. Finally, Vanguard Group Inc. lifted its holdings in FibroGen by 15.1% in the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after acquiring an additional 761,421 shares during the last quarter. Hedge funds and other institutional investors own 57.42% of the company’s stock.

A number of research firms have recently issued reports on FGEN. Jefferies Group restated a “buy” rating and issued a $75.00 price target on shares of FibroGen in a research report on Tuesday, September 12th. Mizuho restated a “hold” rating and issued a $61.00 price target on shares of FibroGen in a research report on Thursday, November 9th. Stifel Nicolaus restated a “buy” rating and issued a $80.00 price target on shares of FibroGen in a research report on Thursday, September 14th. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, William Blair restated an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. FibroGen presently has a consensus rating of “Buy” and a consensus price target of $65.67.

ILLEGAL ACTIVITY WARNING: “Insider Selling: FibroGen, Inc (FGEN) Director Sells $567,000.00 in Stock” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/07/insider-selling-fibrogen-inc-fgen-director-sells-567000-00-in-stock.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.